Convalescent plasma: Clinical trial in Canada for COVID-19 treatment
In plain language
This advisory from Health Canada concerns convalescent plasma, a component of blood from people who have recovered from COVID-19. While there is interest in its use, convalescent plasma has not yet been authorized as a treatment. Health Canada has authorized a nation-wide clinical trial to assess its safety and effectiveness.
What to do
- Learn more about the clinical trial in Canada.
- For information on donor eligibility outside Quebec, visit Canadian Blood Services.
- For information on donor eligibility in Quebec, visit Héma-Québec.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Specific affected products are listed in the official notice.
Do I have this product?
This recall applies to specific products. Details are listed in the official notice.
Frequently Asked Questions
Why was this product recalled?
This advisory from Health Canada concerns convalescent plasma, a component of blood from people who have recovered from COVID-19. While there is interest in its use, convalescent plasma has not yet been authorized as a treatment. Health Canada has authorized a nation-wide clinical trial to assess its safety and effectiveness.
What should consumers do?
Learn more about the clinical trial in Canada. For information on donor eligibility outside Quebec, visit Canadian Blood Services. For information on donor eligibility in Quebec, visit Héma-Québec.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
A potential safety risk has been identified with this product. Stop using it immediately and follow the instructions in the official recall notice.
When was this product recalled?
This product was recalled on May 1, 2020.